Azacitidine
Estrogen Receptor Positive and HER2 Negative Breast Cancer
University Health Network, TorontoSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Estrogen Receptor Positive and HER2 Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole BeOne Medicines | Phase 4 | BB |
FULVESTRANT BeiGene | Phase 2/3 | B |
Cyclophosphamide Puma Biotechnology, Inc. | Phase 3 | B |
Elacestrant GBG Forschungs GmbH | Phase 2 | B |
Carboplatin Fudan University | Phase 3 | B |
View all 24 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →